BML Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

BML Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Buy	573,287 +164,400	+40%	+$399K	0.78%	14
2026 Q1	$1.07M	Hold	408,887	–	–	0.69%	14
2025 Q4	$1.15M	Sell	408,887 -858,613	-68%	-$1.83M	1%	13
2025 Q3	$1.91M	Sell	1,267,500 -554,058	-30%	-$981K	1.75%	10
2025 Q2	$1.79M	Sell	1,821,558 -271,674	-13%	-$217K	1.35%	15
2025 Q1	$1.15M	Hold	2,093,232	–	–	0.93%	16
2024 Q4	$2.89M	Hold	2,093,232	–	–	1.79%	13
2024 Q3	$3.01M	Buy	2,093,232 +49,984	+2%	+$61K	1.77%	13
2024 Q2	$3.11M	Sell	2,043,248 -18,090	-0.9%	-$29.7K	2.22%	11
2024 Q1	$3.59M	Sell	2,061,338 -100	-0%	-$122	2.37%	11
2023 Q4	$2.43M	Buy	+2,061,438	New	+$2.45M	1.84%	14

Other funds holding CNTB

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BML Capital Management's CNTB Position: Q2 2026 in Review

BML Capital Management increased its Connect Biopharma Holdings (CNTB) stake by 40% in Q2 2026, buying an estimated $399K and bringing the position to 573,287 shares worth $1.36M. The position accounts for 0.78% of the portfolio, ranked #14.

BML Capital Management first reported a position in CNTB in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.59M in Q1 2024. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

BML Capital Management held 573,287 shares of Connect Biopharma Holdings worth $1.36M as of Q2 2026.
BML Capital Management bought 164,400 Connect Biopharma Holdings shares in Q2 2026, an estimated $399K.
Connect Biopharma Holdings made up 0.78% of BML Capital Management's portfolio in Q2 2026, its #14 holding.
BML Capital Management first reported a position in Connect Biopharma Holdings in Q4 2023 and has held it in 11 quarters since.
BML Capital Management's Connect Biopharma Holdings position peaked at $3.59M in Q1 2024.
56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.